Last week, the Trump administration announced drastic changes and reductions to federal health programs that support the sickle cell disease community.....

SCDAA is aware of and monitoring the measles outbreaks that have been reported in several states. There is a fair amount.....

As Black History Month ends, we would like to look to the future for our final #SCDHistoryHighlight at the amazing work organizations across the country are doing to create a safer environment for our community. We’ve seen many landmark decisions and groundbreaking treatments in the more than 50 years since SCDAA’s founding, but one thing has remained true throughout – that our member organizations are.....

After our founding, one of SCDAA’s earliest goals was to ensure the National Sickle Cell Anemia Control Act of 1972 was passed. With our early member organizations in tow, Dr. Whitten and the association began to advocate for this landmark piece of legislation. Our #SCDHistoryHighlight this week looks at why this act was so important for moving sickle cell treatment and research forward. During the.....

Last week, we learned about the origins of the Sickle Cell Disease Association of America, Inc. (SCDAA) and the vision for a national coordinated approach to addressing sickle cell disease. This week, our #SCDHistoryHighlight draws attention to the important community-based organizations that joined us in our fight and served as our foundation. During the summer of 1971, the vision for SCDAA – National was formed.....

Our first #SCDHistoryHighlight for Black History Month brings attention to the life and work of SCDAA co-founder Dr. Charles F. Whitten. Dr. Whitten was a pediatric hematologist whose dedication to supporting the health of sickle cell patients paved the way for advances in screening, education and more. His pioneering work makes him one of the most important figures in sickle cell history......

On January 30, 2025, the American Society of Hematology (ASH) published a report that found no evidence to support that physical activity can cause sudden death for individuals with sickle cell trait (SCT) without rhabdomyolysis (muscle breakdown) or heat injury. The article also found that there is not a high-level of evidence that sickle cell trait causes acute pain crises......

.....

Editas Medicine recently announced that they will be making a strategic transition to a in vivo gene editing company. The company intends to develop a transformative in vivo medicine for the treatment of sickle cell disease and beta thalassemia. To learn more, read their FAQs......